Please try another search
Saniona AB (publ), a biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Denmark. It also develops medicines modulating ion channels. The company’s products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity. It also develops SAN711, which has completed Phase 1 clinical stage for neuropathic pain conditions; SAN903 for inflammatory and fibrotic disorders; and SAN2219, that is in preclinical stage for treatment of epilepsy. The company has research and collaboration agreements with Boehringer Ingelheim International GmbH; license agreement with Productos Medix, S.A. de C.V.; research services agreement and a collaboration agreement with Cephagenix ApS; and research collaboration with AstronauTx to identify new treatments for Alzheimer’s disease. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.
Name | Age | Since | Title |
---|---|---|---|
Jorgen Drejer | 67 | 2011 | Founder, Chairman & Deputy CEO |
Carl Johan Sundberg | 64 | 2015 | Independent Director |
Anna Ljung | 42 | 2018 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review